Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.
作者信息
Pagano Livio, Cornely Oliver A, Busca Alessandro, Caira Morena, Cesaro Simone, Gasbarrino Cristiana, Girmenia Corrado, Heinz Werner J, Herbrecht Raoul, Lass-Flörl Cornelia, Nosari Annamaria, Potenza Leonardo, Racil Zdenek, Rickerts Volker, Sheppard Donald C, Simon Arne, Ullmann Andrew J, Valentini Caterina Giovanna, Vehreschild Jörg Janne, Candoni Anna, Vehreschild Maria J G T
机构信息
Livio Pagano.
出版信息
Haematologica. 2013 Oct;98(10):e127-30. doi: 10.3324/haematol.2012.083063. Epub 2013 May 28.
Abstract
摘要
相似文献
1
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.血液系统疾病患者侵袭性毛霉病的联合抗真菌治疗方法：来自SEIFEM和FUNGISCOPE注册研究的报告
Haematologica. 2013 Oct;98(10):e127-30. doi: 10.3324/haematol.2012.083063. Epub 2013 May 28.
2
Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn).对接受侵袭性毛霉菌病治疗的患者进行配对分析：标准治疗与泊沙康唑新制剂（MoveOn）。
J Antimicrob Chemother. 2019 Nov 1;74(11):3315-3327. doi: 10.1093/jac/dkz344.
3
Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy.肝移植术后肝毛霉菌病病例报告：脂质体两性霉素B治疗成功后序贯泊沙康唑治疗
Transplant Proc. 2012 Oct;44(8):2501-2. doi: 10.1016/j.transproceed.2012.07.042.
4
Current controversies in treating invasive zygomycosis.侵袭性毛霉病治疗中的当前争议
J Pediatr Hematol Oncol. 2010 Mar;32(2):83-4. doi: 10.1097/MPH.0b013e3181c2fd6d.
5
Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.泊沙康唑联合两性霉素B是治疗由米根霉引起的小鼠播散性感染的有效疗法。
Antimicrob Agents Chemother. 2008 Oct;52(10):3786-8. doi: 10.1128/AAC.00628-08. Epub 2008 Aug 11.
6
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.泊沙康唑在体外可增强两性霉素B对接合菌菌丝的活性。
Antimicrob Agents Chemother. 2008 Jul;52(7):2636-8. doi: 10.1128/AAC.00492-08. Epub 2008 May 5.
7
Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.打破常规：毛霉病及当前药物治疗选择综述
Ann Pharmacother. 2016 Sep;50(9):747-57. doi: 10.1177/1060028016655425. Epub 2016 Jun 15.
8
Deferasirox in mucormycosis: hopefully, not defeated.地拉罗司治疗毛霉病：有望，而非失败。
J Antimicrob Chemother. 2012 Mar;67(3):783-4. doi: 10.1093/jac/dkr529. Epub 2011 Dec 13.
9
[Two cases of mycoses associated with hematologic disease].[两例与血液系统疾病相关的真菌病]
Jpn J Antibiot. 2008 Oct;61(5):353-4.
10
Deferasirox as adjunctive therapy for mucormycosis.地拉罗司作为黏菌病辅助治疗的应用。
J Antimicrob Chemother. 2012 Mar;67(3):519-20. doi: 10.1093/jac/dkr540. Epub 2011 Dec 20.
引用本文的文献
1
Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds.非曲霉菌属霉菌引起的侵袭性真菌感染的诊断与管理
J Antimicrob Chemother. 2025 Mar 14;80(Supplement_1):i17-i39. doi: 10.1093/jac/dkaf005.
2
Severe dual fungal infection after bispecific antibody therapy: A case of invasive aspergillosis and mucormycosis in immunocompromised patient.双特异性抗体治疗后发生严重双重真菌感染：1例免疫功能低下患者的侵袭性曲霉病和毛霉病
IDCases. 2024 Dec 22;39:e02140. doi: 10.1016/j.idcr.2024.e02140. eCollection 2025.
3
Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit .协同抑制的唑类组合药物和多靶点药物
J Fungi (Basel). 2024 Oct 7;10(10):698. doi: 10.3390/jof10100698.
4
Clinical Characteristics, Prognosis Factors and Metagenomic Next-Generation Sequencing Diagnosis of Mucormycosis in patients With Hematologic Diseases.血液病患者毛霉菌病的临床特征、预后因素和宏基因组下一代测序诊断。
Mycopathologia. 2024 Aug 1;189(4):71. doi: 10.1007/s11046-024-00875-w.
5
Molecular mechanisms that govern infection and antifungal resistance in Mucorales.控制毛霉目真菌感染和抗真菌耐药性的分子机制。
Microbiol Mol Biol Rev. 2024 Mar 27;88(1):e0018822. doi: 10.1128/mmbr.00188-22. Epub 2024 Mar 6.
6
Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.感染植物和人类的跨界真菌病原体以及唑类杀菌剂抗性问题。
Front Microbiol. 2024 Feb 12;15:1354757. doi: 10.3389/fmicb.2024.1354757. eCollection 2024.
7
A Systematic Review of the Therapeutic Outcome of Mucormycosis.毛霉菌病治疗结果的系统评价
Open Forum Infect Dis. 2023 Dec 30;11(1):ofad704. doi: 10.1093/ofid/ofad704. eCollection 2024 Jan.
8
Clinical Features and Treatment Progress of Invasive Mucormycosis in Patients with Hematological Malignancies.血液系统恶性肿瘤患者侵袭性毛霉病的临床特征与治疗进展
J Fungi (Basel). 2023 May 19;9(5):592. doi: 10.3390/jof9050592.
9
What Is New in Pulmonary Mucormycosis?肺毛霉病有哪些新进展？
J Fungi (Basel). 2023 Feb 28;9(3):307. doi: 10.3390/jof9030307.
10
Osteoarticular Mycoses.骨与关节真菌病。
Clin Microbiol Rev. 2022 Dec 21;35(4):e0008619. doi: 10.1128/cmr.00086-19. Epub 2022 Nov 30.
本文引用的文献
1
A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).法国毛霉病的全球分析：RetroZygo 研究（2005-2007 年）。
Clin Infect Dis. 2012 Feb;54 Suppl 1:S35-43. doi: 10.1093/cid/cir880.
2
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.去铁酮-两性霉素 B 脂质体治疗毛霉病（DEFEAT Mucor）研究：一项随机、双盲、安慰剂对照试验。
J Antimicrob Chemother. 2012 Mar;67(3):715-22. doi: 10.1093/jac/dkr375. Epub 2011 Sep 20.
3
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007.欧洲接合菌病：欧洲医学真菌学会（ECMM）接合菌病工作组 2005 年至 2007 年登记的 230 例病例分析。
Clin Microbiol Infect. 2011 Dec;17(12):1859-67. doi: 10.1111/j.1469-0691.2010.03456.x. Epub 2011 Jul 1.
4
Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients.实体器官移植受者的鼻眶脑毛霉病。
Transplantation. 2010 Jul 15;90(1):85-92. doi: 10.1097/tp.0b013e3181dde8fc.
5
Forty-one recent cases of invasive zygomycosis from a global clinical registry.全球临床注册中心的 41 例侵袭性接合菌病近期病例。
J Antimicrob Chemother. 2010 Feb;65(2):296-302. doi: 10.1093/jac/dkp430. Epub 2009 Dec 11.
6
The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis.铁螯合剂地拉罗司增强脂质体两性霉素 B 治疗小鼠侵袭性肺曲霉病的疗效。
J Antimicrob Chemother. 2010 Feb;65(2):289-92. doi: 10.1093/jac/dkp426. Epub 2009 Nov 26.
7
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.泊沙康唑单药或联合治疗小鼠接合菌病。
Antimicrob Agents Chemother. 2009 Feb;53(2):772-5. doi: 10.1128/AAC.01124-08. Epub 2008 Oct 20.
8
Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.泊沙康唑联合两性霉素B是治疗由米根霉引起的小鼠播散性感染的有效疗法。
Antimicrob Agents Chemother. 2008 Oct;52(10):3786-8. doi: 10.1128/AAC.00628-08. Epub 2008 Aug 11.
9
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.泊沙康唑在体外可增强两性霉素B对接合菌菌丝的活性。
Antimicrob Agents Chemother. 2008 Jul;52(7):2636-8. doi: 10.1128/AAC.00492-08. Epub 2008 May 5.
10
In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus.两性霉素B、泊沙康唑及其他四种药物联合应用对根霉的体外活性
J Antimicrob Chemother. 2008 Mar;61(3):755-7. doi: 10.1093/jac/dkn005. Epub 2008 Jan 28.
Zotero 插件